Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Taxanes are a mainstay of treatment for breast cancer, but resistance often develops followed by metastatic disease and mortality. Aiming to reveal the mechanisms underlying taxane resistance, we used breast cancer patient-derived orthoxenografts (PDX). Mimicking clinical behavior, triple-negative breast tumors (TNBCs) from PDX models were more sensitive to docetaxel than luminal tumors, but they progressively acquired resistance upon continuous drug administration. Mechanistically, we found that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands during the acquisition of drug resistance. In the absence of the drug, the resistant CD49f+ population shrinks and taxane sensitivity is restored. We describe a transcriptional signature of resistance, predictive of recurrent disease after chemotherapy in TNBC. Together, these findings identify a CD49f+ population enriched in tumor-initiating ability and chemoresistance properties and evidence a drug holiday effect on the acquired resistance to docetaxel in triple-negative breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 6×
“In breast cancer, a variety of markers (CD44, CD24, EpCAM, CD49f, CD133/2, CD10, and ALDH activity) have been shown to identify CSCs (Al-Hajj et al., 2003; Bachelard-Cascales et al., 2008; Li et al., 2008; Lim et al., 2009; Stingl et al., 2006).”
BackgroundInfluentialThe clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 2×
“Triple-negative breast cancer (TNBC) is a heterogeneous disease with divergent profiles of chemosensitivity and prognosis (Perou et al., 2000; Prat et al., 2010; Shah et al., 2012; Yu et al., 2013).”
BackgroundkConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492 · cited 6×
“In breast cancer, a variety of markers (CD44, CD24, EpCAM, CD49f, CD133/2, CD10, and ALDH activity) have been shown to identify CSCs (Al-Hajj et al., 2003; Bachelard-Cascales et al., 2008; Li et al., 2008; Lim et al., 2009; Stingl et al., 2006).”
BackgroundInfluentialReversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888 · cited 2×
“This regain of sensitivity, the so-called ‘‘drug holiday,’’ has been described for targeted therapies in melanoma (Das Thakur et al., 2013; Sun et al., 2014).”
BackgroundModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730 · cited 1×
“This regain of sensitivity, the so-called ‘‘drug holiday,’’ has been described for targeted therapies in melanoma (Das Thakur et al., 2013; Sun et al., 2014).”
BackgroundHatzis, C. (2011) · JAMA · doi:10.1001/jama.2011.593 · Cited by 699 · cited 9×
“Gene expression analyses of IDB-01S and IDB-01R tumors identified a signature (22 downregulated genes in IDB-01R) that was predictive of residual disease after anthracycline/taxane-based therapy in 166 patients with basal-like disease (GSE25066) (Hatzis et al., 2011) and poor survival in the TCGA dataset, highlighting…”
BackgroundMethodInfluential
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 387
Drug resistance and Cancer stem cells
Li, Y., Wang, Z., Ajani, J. A., & Song, S. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-020-00627-5 · Cited by 331
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Brufsky, A., Kim, S. B., Zvirbule, Ž., Eniu, A., Mebis, J., Sohn, J. H., Wongchenko, M., Chohan, S., Amin, R., Yan, Y., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.065 · Cited by 92
Metadata
- Authors
- Gómez-Miragaya, J., Palafox, M., Paré, L., Yoldi, G., Ferrer, I., Vila, S., Galván, P., Pellegrini, P., Pérez-Montoyo, H., Igea, A., Muñoz, P., Esteller, M., Nebreda, A. R., Urruticoechea, A., Morilla, I., Pernas, S., Climent, F., Soler-Monso, M. T., Petit, A., Serra, V., Prat, A., & González-Suárez, E.
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 8
- Issue
- 5
- Pages
- 1392-1407
- ISSN
- 2213-6711 (ISSN-L)
- OpenAlex
- W2608811728
- Cited by
- 75
- References
- 6
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. https://app.cochat.ai/papers/10.1016/j.stemcr.2017.03.026
- The paper
- Gómez-Miragaya, J., Palafox, M., Paré, L., Yoldi, G., Ferrer, I., Vila, S., Galván, P., Pellegrini, P., Pérez-Montoyo, H., Igea, A., Muñoz, P., Esteller, M., Nebreda, A. R., Urruticoechea, A., Morilla, I., Pernas, S., Climent, F., Soler-Monso, M. T., Petit, A., . . . González-Suárez, E. (2017). Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2017.03.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.